Abstract session: NAFLD - Target identification and drug pipeline

 Metabolism, alcohol and toxicity

Room 3
English
Abstract session
28 August 2020 15:30 - 17:00


Presentations

Title Time

Add to Calendar

AS013 MBOAT7, HSD17B13 and metabolic risk factors in the progression of PNPLA3-associated steatohepatitis
28 August 2020 15:30 - 15:45
AS014 The combination of elafibranor and semaglutide drastically improves fibrosing steatohepatitis and distinctly modulates liver inflammatory signature
28 August 2020 15:45 - 16:00
AS015 Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in  animal models of NASH and fibrosis
28 August 2020 16:00 - 16:15
AS016 Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis
28 August 2020 16:15 - 16:30
AS017 A polygenic risk score for progressive nonalcoholic fatty liver disease risk stratification
28 August 2020 16:30 - 16:45
AS018* Carbohydrate restriction reverses NAFLD by altering hepatic mitochondrial fluxes in humans
28 August 2020 16:45 - 17:00